We Are Developing Life-Changing Therapies Through the Use of Our Proprietary Technologies.

Targeting NETs to Improve Cancer Therapies

  • Substantial body of published proof-of-concept data
  • Systemic adjuvant to:
    • Immune checkpoint inhibitors
    • Chemotherapy
    • Radiotherapy
    • CAR T therapies
  • Adoptive cell therapy for solid cancers

The DNase platform is designed to target Neutrophil Extracellular Traps (“NETs”), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. NETs are expelled by activated neutrophils, in response to microbial or pro-inflammatory challenges. However, excessive production or reduced clearance of NETs can lead to aggravated inflammatory and autoimmune pathologies, as well as creation of pro-tumorigenic niches in the case of cancer growth and metastasis. 

Program Highlights:

  • Exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies
  • Advancing toward first-in-human study
  • Systemic DNase program initially targeting multi-billion-dollar Indications Including pancreatic carcinoma

Learn more about DNase

 Personalized CAR T Platform Targeting Cancers with a Patient- and Tumor-Specific Approach

  • Significantly differentiated, proprietary approach to personalized CAR T therapy targeting tumor specific antigens that are independent of CD19 or other antigens common to all B-Cells.
  • Building on the proven success of CAR T therapy

XCART is a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Lymphomas. The XCART technology, developed by The Scripps Research Institute in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell Lymphomas by generating patient- and tumor-specific CAR T cells.

Program Highlights

  • Advancing preclinical efforts through ongoing research and development collaborations including with The Scripps Research Institute and other institutions in the United States covering design and implementation of the pre-clinical development program, as well as activities supporting process development for clinical manufacturing.
  • Bolstered intellectual property portfolio with issuance of a U.S. patent covering the co-administration of XCART-derived CAR T cells, together with a personalized vaccine designed to enhance the effectiveness of the CAR T therapy.

Learn more about XCART

PolyXen® PSA Technology Platform

Next generation half-life extension platform technology

  • Ongoing royalty stream through license arrangement in the field of blood coagulation disorders
  • Pharmsynthez: filed registration dossier in Russia for Epolong product candidate
  • Potential to partner with additional pharmaceutical companies

PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin (rhEPO) and recombinant Factor VIII (rFVIII).

Xenetic is leveraging PolyXen to partner with biotechnology and pharmaceutical companies. The Company receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders. In addition, Xenetic’s partner, PJSC Pharmsynthez ("Pharmsynthez"), is leveraging the Company’s PolyXen® technology to improve the pharmacological properties of its Epolong (erythropoietin and polysialic acid conjugate) product candidate pursuant to a royalty-bearing collaboration agreement between the Company's wholly owned subsidiary, Lipoxen Technologies Limited, and Pharmsynthez's wholly-owned subsidiary, SynBio LLC. Pharmsynthez has reported that it has started the registration phase of Epolong by filing a registration dossier to obtain approval of Epolong in Russia for the treatment of anemia in patients with chronic kidney disease. The registration dossier is based on previously reported data from Pharmsynthez's Phase 3 clinical trials of Epolong in Russia, which reportedly demonstrated the efficacy of Epolong and its potential to reduce side effects.

Learn more about PolyXen®